Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System

Sponsor
Zimmer Biomet (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT01480440
Collaborator
(none)
200
5
191
40
0.2

Study Details

Study Description

Brief Summary

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

Detailed Description

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be collected and analyzed to monitor pain, function, and survivorship and to confirm the performance of the Trabecular Metal Reverse Shoulder System.

Performance will be evaluated by monitoring the frequency and incidence of adverse events as well as by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Trabecular metal Reverse Shoulder System.

Pain and functional performance will be measured using the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE), survivorship will be based on removal or intended removal of the device, health status will be determined by evaluation of the Short Form Survey12 (SF-12) as well as Adverse Events (AEs) and radiographic parameters analysis of x-rays.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Reverse Should System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Actual Study Start Date :
Jan 1, 2011
Anticipated Primary Completion Date :
Dec 1, 2026
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Trabecular Metal Reverse Shoulder System

Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System

Device: Trabecular Metal Reverse Shoulder System
Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
Other Names:
  • TM Reverse Shoulder System
  • TM Reverse System
  • TM Reverse
  • Outcome Measures

    Primary Outcome Measures

    1. Survivorship [10 Years]

      Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

    Secondary Outcome Measures

    1. Pain and Functional Performance [10 Years]

      Measurements will be based on the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient is > 18 years of age;

    • Patient is skeletally mature;

    • Patient qualifies for primary or revision unilateral or bilateral reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreducible 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff deficiency or failed total shoulder arthroplasty (both glenoid and humeral components require revision);

    • Patient is willing and able to provide written informed consent;

    • Patient is willing and able to cooperate in the required post-operative therapy;

    • Patient is willing and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent;

    • Patient has participated in the Informed Consent process and has signed the Institutional Review Board (IRB)/Ethical Review Board (ERB) approved informed consent.

    Exclusion Criteria:
    • The patient is a prisoner;

    • The patient is mentally incompetent or unable to understand what participation in the study entails;

    • The patient is a known alcohol or drug abuser;

    • The patient is anticipated to be non-compliant;

    • The patient has one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable;

    • The patient has a local/systemic infection;

    • The patient is known to be pregnant;

    • The patient has marked bone loss;

    • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials;

    • The patient is unwilling or unable to give consent or to comply with the follow-up program.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California, San Francisco San Francisco California United States 94143
    2 Norton Orthopaedic & Sports Medicine Louisville Kentucky United States 40241
    3 The Rothman Institute Egg Harbor Township New Jersey United States 08234
    4 The Rothman Institute Philadelphia Pennsylvania United States 19107
    5 Royal Blackburn Hospital Blackburn Lancashire United Kingdom BB2 3HH

    Sponsors and Collaborators

    • Zimmer Biomet

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zimmer Biomet
    ClinicalTrials.gov Identifier:
    NCT01480440
    Other Study ID Numbers:
    • CMU2010-28E
    First Posted:
    Nov 28, 2011
    Last Update Posted:
    Mar 29, 2022
    Last Verified:
    Mar 1, 2022

    Study Results

    No Results Posted as of Mar 29, 2022